DOCSLIB.ORG

1 Table 1S. Genes Over-Expressed in AILT Vs. Normal T-Lymphocytes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Table 1S. Genes Over-Expressed in AILT Vs. Normal T-Lymphocytes Table 1S. Genes over-expressed in AILT vs. normal T-lymphocytes (corresponding to CD4+, CD8+ and HLA-DR+ elements) Over-expression (Z Gene Common GeneBank Description score) 9.38 232544_at AU144916 CDNA FLJ11572 fis, clone HEMBA1003373 9.179 220423_at PLA2G2D NM_012400 phospholipase A2, group IID 9.093 211719_x_at FN1 BC005858 fibronectin 1 9.005 204163_at EMILIN1 NM_007046 elastin microfibril interfacer 1 8.642 216442_x_at FN1 AK026737 fibronectin 1 8.552 220690_s_at DKFZp566O084 NM_015510 DKFZP566O084 protein 8.204 210072_at CCL19 U88321 chemokine (CC motif) ligand 19 7.996 230047_at FLJ32810 BF439533 nab67d10.x1 Soares_NSF_F8_9W_OT_PA_P_S1 Homo sapiens cDNA clone IMAGE:3272875 3', mRNA sequence. 7.641 225575_at LIFR AI680541 leukemia inhibitory factor receptor 7.59 215076_s_at COL3A1 AU144167 collagen, type III, alpha 1 (EhlersDanlos syndrome type IV, autosomal dominant) 7.581 204570_at COX7A1 NM_001864 cytochrome c oxidase subunit VIIa polypeptide 1 (muscle) 7.56 217767_at C3 NM_000064 complement component 3 7.411 211981_at COL4A1 NM_001845 collagen, type IV, alpha 1 7.384 204606_at CCL21 NM_002989 chemokine (CC motif) ligand 21 7.384 201162_at IGFBP7 NM_001553 insulinlike growth factor binding protein 7 7.2 208747_s_at C1S M18767 complement component 1, s subcomponent 7.102 203915_at CXCL9 NM_002416 chemokine (CXC motif) ligand 9 6.938 222162_s_at ADAMTS1 AK023795 a disintegrinlike and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 1 6.931 205890_s_at UBD NM_006398 ubiquitin D 6.813 222885_at EMCN AF205940 endomucin 6.785 201852_x_at COL3A1 AI813758 collagen, type III, alpha 1 (EhlersDanlos syndrome type IV, autosomal dominant) 6.757 212091_s_at COL6A1 AI141603 collagen, type VI, alpha 1 6.755 201744_s_at LUM NM_002345 lumican 6.712 212187_x_at PTGDS NM_000954 prostaglandin D2 synthase 21kDa (brain) 6.627 208791_at CLU M25915 clusterin (complement lysis inhibitor, SP40,40, sulfated glycoprotein 2, testosteronerepressed prostate message 2, apolipoprotein J) 6.623 208792_s_at CLU M25915 clusterin (complement lysis inhibitor, SP40,40, sulfated glycoprotein 2, testosteronerepressed prostate message 2, apolipoprotein J) 6.616 212464_s_at FN1 X02761 fibronectin 1 6.588 209183_s_at C10orf10 AL136653 chromosome 10 open reading frame 10 6.515 218541_s_at C8orf4 NM_020130 chromosome 8 open reading frame 4 6.492 211161_s_at AF130082 predicted protein of HQ3121; Homo sapiens clone FLC1492 PRO3121 mRNA, complete cds. 1 6.436 226950_at T63524 yc07b04.s1 Stratagene lung (#937210) Homo sapiens cDNA clone IMAGE:79951 3', mRNA sequence. 6.373 212713_at MFAP4 R72286 microfibrillarassociated protein 4 6.286 210495_x_at FN1 AF130095 fibronectin 1 6.217 201141_at GPNMB NM_002510 glycoprotein (transmembrane) nmb 6.156 211748_x_at PTGDS BC005939 prostaglandin D2 synthase 21kDa (brain) 6.153 212077_at CALD1 AL583520 caldesmon 1 6.108 226636_at PLD1 AI378587 phospholipase D1, phophatidylcholinespecific 6.034 235229_at OR2I6 AI694413 wd83d12.x1 NCI_CGAP_Lu24 Homo sapiens cDNA clone IMAGE:2338199 3', mRNA sequence. 6.032 223395_at TARSH AB056106 target of NeshSH3 6.031 209120_at NR2F2 AL037401 nuclear receptor subfamily 2, group F, member 2 5.997 211964_at COL4A2 X05610 collagen, type IV, alpha 2 5.966 209488_s_at RBPMS D84109 RNA binding protein with multiple splicing 5.953 225353_s_at C1QG AI184968 qe51c05.x1 Soares_fetal_lung_NbHL19W Homo sapiens cDNA clone IMAGE:1742504 3' similar to SW:C1QC_HUMAN P02747 COMPLEMENT C1Q SUBCOMPONENT, C CHAIN PRECURSOR. ;, mRNA sequence. 5.946 209395_at CHI3L1 M80927 chitinase 3like 1 (cartilage glycoprotein39) 5.946 201163_s_at IGFBP7 NM_001553 insulinlike growth factor binding protein 7 5.941 211980_at COL4A1 AI922605 collagen, type IV, alpha 1 5.883 203382_s_at APOE NM_000041 apolipoprotein E 5.883 201616_s_at CALD1 AL577531 caldesmon 1 5.881 215388_s_at HFL1 X56210 H factor (complement)like 1 5.868 217757_at A2M NM_000014 alpha2macroglobulin 5.803 204416_x_at APOC1 NM_001645 apolipoprotein CI 5.783 218232_at C1QA NM_015991 complement component 1, q subcomponent, alpha polypeptide 5.773 202052_s_at RAI14 NM_015577 retinoic acid induced 14 5.769 203381_s_at APOE N33009 apolipoprotein E 5.756 1556499_s_at COL1A1 BE221212 hu22a05.x1 NCI_CGAP_Mel15 Homo sapiens cDNA clone IMAGE:3170768 3' similar to gb:K01228 PROCOLLAGEN ALPHA 1(I) CHAIN PRECURSOR (HUMAN);, mRNA sequence. 5.741 202992_at C7 NM_000587 complement component 7 5.74 201645_at TNC NM_002160 tenascin C (hexabrachion) 5.733 200795_at SPARCL1 NM_004684 SPARClike 1 (mast9, hevin) 5.73 219825_at CYP26B1 NM_019885 cytochrome P450, family 26, subfamily B, polypeptide 1 5.725 202237_at NNMT NM_006169 nicotinamide Nmethyltransferase 5.71 209396_s_at CHI3L1 M80927 chitinase 3like 1 (cartilage glycoprotein39) 5.71 202403_s_at COL1A2 AA788711 collagen, type I, alpha 2 5.704 206134_at ADAMDEC1 NM_014479 ADAMlike, decysin 1 5.695 202112_at VWF NM_000552 von Willebrand factor 5.62 200665_s_at SPARC NM_003118 secreted protein, acidic, cysteinerich (osteonectin) 5.571 202953_at C1QB NM_000491 complement component 1, q subcomponent, beta polypeptide 2 5.557 226695_at PRRX1 AA775472 paired related homeobox 1 5.491 200986_at SERPING1 NM_000062 serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary) 5.417 203868_s_at VCAM1 NM_001078 vascular cell adhesion molecule 1 5.362 209821_at C9orf26 AB024518 chromosome 9 open reading frame 26 (NFHEV) 5.361 202404_s_at COL1A2 NM_000089 collagen, type I, alpha 2 5.347 220532_s_at LR8 NM_014020 LR8 protein 5.323 205547_s_at TAGLN NM_003186 transgelin 5.318 213428_s_at COL6A1 AA292373 collagen, type VI, alpha 1 5.291 202310_s_at COL1A1 K01228 collagen, type I, alpha 1 5.264 209496_at RARRES2 BC000069 retinoic acid receptor responder (tazarotene induced) 2 5.26 1558828_s_at DKFZp586C0721 AL703532 hypothetical protein DKFZp586C0721 5.193 209121_x_at NR2F2 M64497 nuclear receptor subfamily 2, group F, member 2 5.137 217853_at TENS1 NM_022748 tensinlike SH2 domain containing 1 5.124 219134_at ELTD1 NM_022159 5.113 212067_s_at C1R AL573058 complement component 1, r subcomponent 5.044 201617_x_at CALD1 NM_004342 caldesmon 1 5.029 216598_s_at CCL2 S69738 chemokine (CC motif) ligand 2 4.982 206210_s_at CETP NM_000078 cholesteryl ester transfer protein, plasma 4.979 201058_s_at MYL9 NM_006097 myosin, light polypeptide 9, regulatory 4.97 201655_s_at HSPG2 M85289 heparan sulfate proteoglycan 2 (perlecan) 4.948 226814_at ADAMTS9 AI431730 a disintegrinlike and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 9 4.89 204533_at CXCL10 NM_001565 chemokine (CXC motif) ligand 10 4.889 202838_at FUCA1 NM_000147 fucosidase, alphaL 1, tissue 4.865 204036_at EDG2 AW269335 endothelial differentiation, lysophosphatidic acid Gproteincoupled receptor, 2 4.83 204879_at T1A2 NM_006474 lung typeI cell membraneassociated glycoprotein 4.808 226436_at RASSF4 N49935 Ras association (RalGDS/AF6) domain family 4 4.803 209074_s_at TU3A AL050264 TU3A protein 4.799 223044_at SLC40A1 AL136944 solute carrier family 40 (ironregulated transporter), member 1 4.756 203920_at NR1H3 NM_005693 nuclear receptor subfamily 1, group H, member 3 4.755 209070_s_at RGS5 AI183997 regulator of Gprotein signalling 5 4.744 201667_at GJA1 NM_000165 gap junction protein, alpha 1, 43kDa (connexin 43) 4.717 203936_s_at MMP9 NM_004994 matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) 4.613 209687_at CXCL12 U19495 chemokine (CXC motif) ligand 12 (stromal cellderived factor 1) 4.612 218345_at HCA112 NM_018487 hepatocellular carcinomaassociated antigen 112 4.571 213455_at LOC92689 W87466 hypothetical protein BC001096 4.567 201505_at LAMB1 NM_002291 laminin, beta 1 4.556 204112_s_at HNMT NM_006895 histamine Nmethyltransferase 3 4.55 208789_at PTRF BC004295 polymerase I and transcript release factor 4.504 1555724_s_at TAGLN BC010946 transgelin 4.498 226621_at FGG AI133452 fibrinogen, gamma polypeptide 4.463 208782_at FSTL1 BC000055 follistatinlike 1 4.453 201193_at IDH1 NM_005896 isocitrate dehydrogenase 1 (NADP+), soluble 4.425 224823_at MYLK AA526844 MSTP083 mRNA, complete cds 4.369 202766_s_at FBN1 NM_000138 fibrillin 1 (Marfan syndrome) 4.369 223235_s_at SMOC2 AB014737 SPARC related modular calcium binding 2 4.366 213553_x_at APOC1 W79394 apolipoprotein CI 4.354 212884_x_at APOE AI358867 apolipoprotein E 4.324 223820_at RBP5 AY007436 retinol binding protein 5, cellular 4.314 209071_s_at RGS5 AF159570 regulator of Gprotein signalling 5 4.292 209869_at ADRA2A AF284095 adrenergic, alpha2A, receptor 4.28 209289_at NFIB AI700518 nuclear factor I/B 4.258 203477_at COL15A1 NM_001855 collagen, type XV, alpha 1 4.249 202252_at RAB13 NM_002870 RAB13, member RAS oncogene family 4.244 225664_at COL12A1 AA788946 collagen, type XII, alpha 1 4.235 202465_at PCOLCE NM_002593 procollagen Cendopeptidase enhancer 4.227 209210_s_at PLEKHC1 Z24725 pleckstrin homology domain containing, family C (with FERM domain) member 1 4.222 202800_at SLC1A3 NM_004172 solute carrier family 1 (glial high affinity glutamate transporter), member 3 4.212 203060_s_at PAPSS2 AF074331 Homo sapiens PAPS synthetase2 (PAPSS2) mRNA, complete cds. 4.183 202133_at TAZ BF674349 transcriptional coactivator with PDZbinding motif (TAZ) 4.151 212724_at ARHE BG054844 ras homolog gene family, member E 4.115 220301_at C18orf14 NM_024781 hypothetical protein FLJ23594 4.114 203131_at PDGFRA NM_006206 plateletderived growth factor receptor, alpha polypeptide 4.113 208335_s_at FY NM_002036 Duffy blood group 4.104 212667_at SPARC AL575922
Load more

Recommended publications
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • Molecular Markers of Serine Protease Evolution
    The EMBO Journal Vol. 20 No. 12 pp. 3036±3045, 2001 Molecular markers of serine protease evolution Maxwell M.Krem and Enrico Di Cera1 ment and specialization of the catalytic architecture should correspond to signi®cant evolutionary transitions in the Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Box 8231, St Louis, history of protease clans. Evolutionary markers encoun- MO 63110-1093, USA tered in the sequences contributing to the catalytic apparatus would thus give an account of the history of 1Corresponding author e-mail: [email protected] an enzyme family or clan and provide for comparative analysis with other families and clans. Therefore, the use The evolutionary history of serine proteases can be of sequence markers associated with active site structure accounted for by highly conserved amino acids that generates a model for protease evolution with broad form crucial structural and chemical elements of applicability and potential for extension to other classes of the catalytic apparatus. These residues display non- enzymes. random dichotomies in either amino acid choice or The ®rst report of a sequence marker associated with serine codon usage and serve as discrete markers for active site chemistry was the observation that both AGY tracking changes in the active site environment and and TCN codons were used to encode active site serines in supporting structures. These markers categorize a variety of enzyme families (Brenner, 1988). Since serine proteases of the chymotrypsin-like, subtilisin- AGY®TCN interconversion is an uncommon event, it like and a/b-hydrolase fold clans according to phylo- was reasoned that enzymes within the same family genetic lineages, and indicate the relative ages and utilizing different active site codons belonged to different order of appearance of those lineages.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • 1 Metabolic Dysfunction Is Restricted to the Sciatic Nerve in Experimental
    Page 1 of 255 Diabetes Metabolic dysfunction is restricted to the sciatic nerve in experimental diabetic neuropathy Oliver J. Freeman1,2, Richard D. Unwin2,3, Andrew W. Dowsey2,3, Paul Begley2,3, Sumia Ali1, Katherine A. Hollywood2,3, Nitin Rustogi2,3, Rasmus S. Petersen1, Warwick B. Dunn2,3†, Garth J.S. Cooper2,3,4,5* & Natalie J. Gardiner1* 1 Faculty of Life Sciences, University of Manchester, UK 2 Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK 3 Centre for Endocrinology and Diabetes, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, UK 4 School of Biological Sciences, University of Auckland, New Zealand 5 Department of Pharmacology, Medical Sciences Division, University of Oxford, UK † Present address: School of Biosciences, University of Birmingham, UK *Joint corresponding authors: Natalie J. Gardiner and Garth J.S. Cooper Email: [email protected]; [email protected] Address: University of Manchester, AV Hill Building, Oxford Road, Manchester, M13 9PT, United Kingdom Telephone: +44 161 275 5768; +44 161 701 0240 Word count: 4,490 Number of tables: 1, Number of figures: 6 Running title: Metabolic dysfunction in diabetic neuropathy 1 Diabetes Publish Ahead of Print, published online October 15, 2015 Diabetes Page 2 of 255 Abstract High glucose levels in the peripheral nervous system (PNS) have been implicated in the pathogenesis of diabetic neuropathy (DN). However our understanding of the molecular mechanisms which cause the marked distal pathology is incomplete. Here we performed a comprehensive, system-wide analysis of the PNS of a rodent model of DN.
    [Show full text]
  • Serum Albumin OS=Homo Sapiens
    Protein Name Cluster of Glial fibrillary acidic protein OS=Homo sapiens GN=GFAP PE=1 SV=1 (P14136) Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 Cluster of Isoform 3 of Plectin OS=Homo sapiens GN=PLEC (Q15149-3) Cluster of Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 (P68871) Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 Cluster of Tubulin beta-3 chain OS=Homo sapiens GN=TUBB3 PE=1 SV=2 (Q13509) Cluster of Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 (P60709) Cluster of Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 (P68363) Cluster of Isoform 2 of Spectrin alpha chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTAN1 (Q13813-2) Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 Cluster of Spectrin beta chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTBN1 PE=1 SV=2 (Q01082) Cluster of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM PE=1 SV=4 (P14618) Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 Cytoplasmic dynein 1 heavy chain 1 OS=Homo sapiens GN=DYNC1H1 PE=1 SV=5 Cluster of ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide OS=Homo sapiens GN=ATP1A2 PE=3 SV=1 (B1AKY9) Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 Dihydropyrimidinase-related protein 2 OS=Homo sapiens GN=DPYSL2 PE=1 SV=1 Cluster of Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 (P12814) 60 kDa heat shock protein, mitochondrial OS=Homo
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Transcriptome-Wide Profiling of Cerebral Cavernous Malformations
    www.nature.com/scientificreports OPEN Transcriptome-wide Profling of Cerebral Cavernous Malformations Patients Reveal Important Long noncoding RNA molecular signatures Santhilal Subhash 2,8, Norman Kalmbach3, Florian Wegner4, Susanne Petri4, Torsten Glomb5, Oliver Dittrich-Breiholz5, Caiquan Huang1, Kiran Kumar Bali6, Wolfram S. Kunz7, Amir Samii1, Helmut Bertalanfy1, Chandrasekhar Kanduri2* & Souvik Kar1,8* Cerebral cavernous malformations (CCMs) are low-fow vascular malformations in the brain associated with recurrent hemorrhage and seizures. The current treatment of CCMs relies solely on surgical intervention. Henceforth, alternative non-invasive therapies are urgently needed to help prevent subsequent hemorrhagic episodes. Long non-coding RNAs (lncRNAs) belong to the class of non-coding RNAs and are known to regulate gene transcription and involved in chromatin remodeling via various mechanism. Despite accumulating evidence demonstrating the role of lncRNAs in cerebrovascular disorders, their identifcation in CCMs pathology remains unknown. The objective of the current study was to identify lncRNAs associated with CCMs pathogenesis using patient cohorts having 10 CCM patients and 4 controls from brain. Executing next generation sequencing, we performed whole transcriptome sequencing (RNA-seq) analysis and identifed 1,967 lncRNAs and 4,928 protein coding genes (PCGs) to be diferentially expressed in CCMs patients. Among these, we selected top 6 diferentially expressed lncRNAs each having signifcant correlative expression with more than 100 diferentially expressed PCGs. The diferential expression status of the top lncRNAs, SMIM25 and LBX2-AS1 in CCMs was further confrmed by qRT-PCR analysis. Additionally, gene set enrichment analysis of correlated PCGs revealed critical pathways related to vascular signaling and important biological processes relevant to CCMs pathophysiology.
    [Show full text]
  • Preclinical Characterization of Dostarlimab, a Therapeutic Anti-PD
    MABS 2021, VOL. 13, NO. 1, e1954136 (12 pages) https://doi.org/10.1080/19420862.2021.1954136 REPORTS Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models Sujatha Kumara*, Srimoyee Ghoshb, Geeta Sharmac, Zebin Wangd, Marilyn R. Kehrye, Margaret H. Marinof, Tamlyn Y. Nebenf, Sharon Lug, Shouqi Luoh, Simon Robertsi, Sridhar Ramaswamyj, Hadi Danaeek, and David Jenkinsl aTranslational Research, Immuno-Oncology, Checkmate Pharmaceuticals, Cambridge, MA, USA; bOncology Experimental Medicine Unit, GlaxoSmithKline, Waltham, MA, USA; cSynthetic Lethal Research Unit, Oncolog, GlaxoSmithKline, Waltham, MA, USA; dTranslational Strategy & Research, GlaxoSmithKline,Waltham, MA, USA; eCell Biology, AnaptysBio, Inc,San Diego, CA, USA; fProgram Management, AnaptysBio, Inc, San Diego, CA, USA; gClinical Pharmacology, Scholar Rock, Cambridge, MA, USA; hToxicology, Atea Pharmaceuticals, Boston, MA, USA; iNonclinical Development, Research In Vivo/In Vitro Translation, GlaxoSmithKline, Waltham, MA, USA; jGoogle Ventures, Cambridge, MA, USA; kTranslational Medicine, Blue Print Medicines, Cambridge, MA, USA; lExternal Innovations, IPSEN, Cambridge, MA, USA ABSTRACT ARTICLE HISTORY Inhibitors of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the Received 17 December 2020 treatment landscape for patients with cancer. Clinical activity of anti-PD-(L)1 antibodies has resulted in Revised 2 July 2021 increased median overall survival and durable responses in patients across selected tumor types. To date, Accepted 7 July 2021 6 PD-1 and PD-L1, here collectively referred to as PD-(L)1, pathway inhibitors are approved by the US Food KEYWORDS and Drug Administration for clinical use.
    [Show full text]
  • Microrna Regulatory Pathways in the Control of the Actin–Myosin Cytoskeleton
    cells Review MicroRNA Regulatory Pathways in the Control of the Actin–Myosin Cytoskeleton , , Karen Uray * y , Evelin Major and Beata Lontay * y Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; [email protected] * Correspondence: [email protected] (K.U.); [email protected] (B.L.); Tel.: +36-52-412345 (K.U. & B.L.) The authors contributed equally to the manuscript. y Received: 11 June 2020; Accepted: 7 July 2020; Published: 9 July 2020 Abstract: MicroRNAs (miRNAs) are key modulators of post-transcriptional gene regulation in a plethora of processes, including actin–myosin cytoskeleton dynamics. Recent evidence points to the widespread effects of miRNAs on actin–myosin cytoskeleton dynamics, either directly on the expression of actin and myosin genes or indirectly on the diverse signaling cascades modulating cytoskeletal arrangement. Furthermore, studies from various human models indicate that miRNAs contribute to the development of various human disorders. The potentially huge impact of miRNA-based mechanisms on cytoskeletal elements is just starting to be recognized. In this review, we summarize recent knowledge about the importance of microRNA modulation of the actin–myosin cytoskeleton affecting physiological processes, including cardiovascular function, hematopoiesis, podocyte physiology, and osteogenesis. Keywords: miRNA; actin; myosin; actin–myosin complex; Rho kinase; cancer; smooth muscle; hematopoiesis; stress fiber; gene expression; cardiovascular system; striated muscle; muscle cell differentiation; therapy 1. Introduction Actin–myosin interactions are the primary source of force generation in mammalian cells. Actin forms a cytoskeletal network and the myosin motor proteins pull actin filaments to produce contractile force. All eukaryotic cells contain an actin–myosin network inferring contractile properties to these cells.
    [Show full text]
  • Novel Myosin Mutations for Hereditary Hearing Loss Revealed by Targeted Genomic Capture and Massively Parallel Sequencing
    European Journal of Human Genetics (2014) 22, 768–775 & 2014 Macmillan Publishers Limited All rights reserved 1018-4813/14 www.nature.com/ejhg ARTICLE Novel myosin mutations for hereditary hearing loss revealed by targeted genomic capture and massively parallel sequencing Zippora Brownstein1,6, Amal Abu-Rayyan2,6, Daphne Karfunkel-Doron1, Serena Sirigu3, Bella Davidov4, Mordechai Shohat1,4, Moshe Frydman1,5, Anne Houdusse3, Moien Kanaan2 and Karen B Avraham*,1 Hereditary hearing loss is genetically heterogeneous, with a large number of genes and mutations contributing to this sensory, often monogenic, disease. This number, as well as large size, precludes comprehensive genetic diagnosis of all known deafness genes. A combination of targeted genomic capture and massively parallel sequencing (MPS), also referred to as next-generation sequencing, was applied to determine the deafness-causing genes in hearing-impaired individuals from Israeli Jewish and Palestinian Arab families. Among the mutations detected, we identified nine novel mutations in the genes encoding myosin VI, myosin VIIA and myosin XVA, doubling the number of myosin mutations in the Middle East. Myosin VI mutations were identified in this population for the first time. Modeling of the mutations provided predicted mechanisms for the damage they inflict in the molecular motors, leading to impaired function and thus deafness. The myosin mutations span all regions of these molecular motors, leading to a wide range of hearing phenotypes, reinforcing the key role of this family of proteins in auditory function. This study demonstrates that multiple mutations responsible for hearing loss can be identified in a relatively straightforward manner by targeted-gene MPS technology and concludes that this is the optimal genetic diagnostic approach for identification of mutations responsible for hearing loss.
    [Show full text]
  • Quantikine® ELISA
    Quantikine® ELISA Human Granzyme B Immunoassay Catalog Number DGZB00 For the quantitative determination of human Granzyme B concentrations in culture supernates. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................3 PRECAUTIONS .........................................................................................................................................................................4 SAMPLE COLLECTION & STORAGE .................................................................................................................................4
    [Show full text]